Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
119 hedge funds and large institutions have $3.07B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 54 increasing their positions, 25 reducing their positions, and 29 closing their positions.
116% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 25
5% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $12.8M
5% less funds holding
Funds holding: 125 → 119 (-6)
17% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 29
30% less capital invested
Capital invested by funds: $4.41B → $3.07B (-$1.33B)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$48.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$23.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$18.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.7M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$38.6M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$23.9M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$22.5M |
| 4 |
Alkeon Capital Management
New York
|
-$22.2M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$18.5M |
CERE Hedge Fund Activity: Q3 2023 in Review
119 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q3 2023, worth a combined $3.07B — down 30% from $4.41B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of CERE and 24 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 54 added.
The largest buyer was Millennium Management, adding an estimated $48.8M. The largest seller was Federated Hermes, exiting entirely with an estimated $38.6M sold.
- 119 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q3 2023, down from 125 in Q2 2023.
- Funds reported $3.07B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q3 2023, down 30% quarter-over-quarter.
- 24 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q3 2023 and 29 closed out, a net change of -5 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q3 2023 was Millennium Management, an estimated $48.8M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q3 2023 was Federated Hermes, an estimated $38.6M sold.
Based on aggregated 13F filings for Q3 2023.